Search company, investor...

Inagen Aps


Other Investors | Alive

About Inagen Aps

Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.

Headquarters Location

150 Allens Creek Road

Rochester, New York, 14618,

United States

Missing: Inagen Aps's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Inagen Aps's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Inagen Aps Patents

Inagen Aps has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, HIV/AIDS, Immune system, Cytokines


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, HIV/AIDS, Immune system, Cytokines



Inagen Aps Frequently Asked Questions (FAQ)

  • Where is Inagen Aps's headquarters?

    Inagen Aps's headquarters is located at 150 Allens Creek Road, Rochester.

  • What is Inagen Aps's latest funding round?

    Inagen Aps's latest funding round is Other Investors.

  • Who are the investors of Inagen Aps?

    Investors of Inagen Aps include Novo Holdings.

  • Who are Inagen Aps's competitors?

    Competitors of Inagen Aps include Intarcia Therapeutics, Rigel Pharmaceuticals, Intercept Pharmaceuticals, Anacor Pharmaceuticals, GlobeImmune and 10 more.

Compare Inagen Aps to Competitors

Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Tioga Pharmaceuticals

Tioga Pharmaceuticals, is focused on the development of therapies for the treatment of gastrointestinal diseases. Tioga is developing asimadoline in Phase 3 clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS). The company was founded in 2005 and is based in San Diego, California.

Verus Pharmaceuticals

Verus Pharmaceuticals is developing products treating asthma


JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Diasome Pharmaceuticals

Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.